Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of ADI-100 for Type-1-diabetes-mellitus

Next Previous
X
Search
Trial Profile

Clinical study of ADI-100 for Type-1-diabetes-mellitus

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADI 100 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 12 Dec 2024 According to a ADiTxT Therapeutics media release, Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025
    • 23 Aug 2023 New trial record
    • 18 Aug 2023 According to a ADiTxT Therapeutics media release, Clinical trial applications for psoriasis is expected to be filed with the German Health Authority in Q1 2024. Stability program is completed and the company intend to finalize the CTA documents and apply for regulatory approval to perform clinical trials in T1D and psoriasis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top